title: Prolonged hypocalcemia after zoledronic acid in a patient with metastatic prostate carcinoma: did zoledronic acid trigger osteoblastic activity and avid calcium uptake?
authors.affiliation: Nottingham University Hospitals NHS Trust, Nottingham City Hospital Campus, Nottingham, UK. joon.ho@nhs.net
authors.forename: Joon Wee
authors.initials: JW
authors.lastname: Ho
authors.forename: Santhanam
authors.initials: S
authors.lastname: Sundar
mesh_terms: D000368:Aged; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D002118:Calcium / Q000378:metabolism*; D004164:Diphosphonates / Q000009:adverse effects*; D006801:Humans; D006996:Hypocalcemia / Q000139:chemically induced*; D007093:Imidazoles / Q000009:adverse effects*; D008297:Male; D010006:Osteoblasts / Q000187:drug effects* / Q000473:pathology; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D002118:Calcium